Sialic acid-binding immunoglobulin-like lectin 10 (SIGLEC10) is a microglia-specific surface receptor in the central nervous system, whose expression has been increasingly implicated in regulating microglial responses and identified as a genetic driver of amyloid plaque formation during Alzheimer’s disease (AD) progression.
In the tumor microenvironment, cancer cells activate various signaling pathways to promote their growth. This includes the formation of blood vessels. However, the circulatory system is not the only one attracted to the tumor. Researchers at Sanford Research have uncovered a mechanism to circumvent the immune response that would destroy them.
Scientists from Luoyang Accendatech Co. Ltd. and Tianjin Accendatech Technology Co. Ltd. have disclosed fluorine-containing parthenolide derivatives and their prodrugs reported to be useful for the treatment of cancer.
Pheon Therapeutics Ltd. has identified antibody-drug conjugates comprising antibodies targeting tumor associated antigens covalently linked to cytotoxic drugs through linker reported to be useful for the treatment of cancer.
Astrazeneca AB has synthesized nicotinamide N-methyltransferase (NNMT) inhibitors reported to be useful for the treatment of chronic kidney disease, acute kidney injury and diabetic nephropathy.
Haisco Pharmaceutical Group Co. Ltd. has prepared and tested glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes and obesity.
Casi Pharmaceuticals Inc. announced the U.S. FDA has cleared its IND application for CID-103, a monoclonal antibody targeting CD-38 for the prevention of antibody-mediated rejection (AMR) of kidney allografts. The company plans to initiate a phase I study in adults with active and chronic active renal allograft AMR.
At the Alzheimer's Association International Conference (AAIC) 2025, researchers from Acadia Pharmaceuticals Inc. have presented novel results on the assessment of the pharmacologic and pharmacokinetic (PK) properties and nonclinical safety of ACP-204.